The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro.
about
Topical Delivery of Tenofovir Disoproxil Fumarate and Emtricitabine from Pod-Intravaginal Rings Protects Macaques from Multiple SHIV ExposuresReduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutationsGenetic Consequences of Antiviral Therapy on HIV-1.Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b).An Enhanced Emtricitabine-Loaded Long-Acting Nanoformulation for Prevention or Treatment of HIV Infection.Inhibition of Plasmodium Hepatic Infection by Antiretroviral Compounds.
P2860
The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The combined anti-HIV-1 activi ...... gh levels of synergy in vitro.
@en
The combined anti-HIV-1 activi ...... gh levels of synergy in vitro.
@nl
type
label
The combined anti-HIV-1 activi ...... gh levels of synergy in vitro.
@en
The combined anti-HIV-1 activi ...... gh levels of synergy in vitro.
@nl
prefLabel
The combined anti-HIV-1 activi ...... gh levels of synergy in vitro.
@en
The combined anti-HIV-1 activi ...... gh levels of synergy in vitro.
@nl
P2093
P2860
P356
P1476
The combined anti-HIV-1 activi ...... gh levels of synergy in vitro.
@en
P2093
Damian M McColl
Kirsten L White
Michael D Miller
Rebecca Hluhanich
Rima Kulkarni
P2860
P304
P356
10.1128/AAC.03591-14
P407
P577
2014-08-04T00:00:00Z